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The mammalian target of rapamycin (mTOR) has emerged as a critical effector in cell-signaling 
pathways commonly deregulated in human cancers. This has led to the prediction that mTOR 
inhibitors may be useful in oncology, and derivatives of one such molecule, rapamycin (from which 
mTOR derives its name), are currently in clinical development. In this review, we discuss recent 
progress in understanding mTOR signaling, paying particular attention to its relevance in cancer. 
We further discuss the use of rapamycin in oncology and conclude with a discussion on the future 
of mTOR-targeted therapy.Introduction
The study of rapamycin continues to bring surprises 
to the signal transduction aficionados, revealing many 
new signaling molecules and a network increasingly 
viewed as important in cancer. In the early 1990s, semi-
nal studies in yeast and mammalian systems identified 
a large 250 kDa protein as the drug’s cellular target, 
which in mammals was named the mammalian target 
of rapamycin (mTOR). Over the next 10 years, scien-
tists used rapamycin to uncover mTOR-dependent 
processes showing that mTOR regulates cell growth 
by controlling mRNA translation, ribosome biogenesis, 
autophagy, and metabolism (Figure 1A) (reviewed in 
Guertin and Sabatini, 2005; Sarbassov et al., 2005a; 
Wullschleger et al., 2006).
Growth factors and nutrients regulate mTOR, indicat-
ing that mTOR is at the interface of two different growth 
signals. Nearly a decade after the discovery of mTOR, 
researchers found that mTOR nucleates a rapamycin- 
and nutrient-sensitive multiprotein complex (now called 
mTORC1) (Hara et al., 2002; Kim et al., 2002; Loewith 
et al., 2002). Following soon after was the unexpected 
identification of a second growth-factor-sensitive but 
nutrient-insensitive mTOR-containing complex called 
mTORC2 (Jacinto et al., 2004; Loewith et al., 2002; Sar-
bassov et al., 2004). Unlike its mTORC1 sibling, rapamycin 
does not bind to mTORC2, and consequently, mTORC2 
is often called the “rapamycin-insensitive complex.” By 
outfitting itself with mTORC1- or mTORC2-specific pro-
teins, mTOR acquires different substrate specificities. 
The discovery of mTORC2 provided conclusive evidence 
to the lurking suspicions that rapamycin did not inhibit 
all of mTOR’s functions.
A prevailing model suggests that cancers depend-
ent upon activation of the oncoprotein AKT rely on sub-
sequent activation of mTORC1 to drive tumorigenesis. 
This “addiction” to mTORC1 signaling by some cancers 
has invigorated the clinical development in oncology of the mTORC1-inhibitor rapamycin. Despite the seem-
ingly clear mechanism of action of rapamycin and sound 
rationale for its use in cancer therapy, first-generation 
mTOR inhibitors have had only modest and unpredictable 
successes in clinical trials. A twist in the mTOR story has 
emerged with the finding that mTOR, when assembled 
into mTORC2, directly phosphorylates and activates AKT, 
perhaps placing mTOR on both sides of the AKT signaling 
hub. Unexpectedly, rapamycin can inhibit AKT by disrupt-
ing mTORC2 assembly, but only in some cell types. These 
discoveries raise a number of questions regarding the 
development and application of mTOR inhibitors. In this 
review, we discuss recent advances in our understanding 
of mTOR biology and its relevance to the clinical develop-
ment of mTOR inhibitors for oncology.
mTORC1 Signaling in Cancer
Besides mTOR, mTORC1 contains RAPTOR (regulatory 
associated protein of mTOR), mLST8 (also known as 
GβL), and PRAS40 (proline-rich AKT substrate 40 kDa) 
(Haar et al., 2007; Hara et al., 2002; Kim et al., 2002, 
2003; Loewith et al., 2002; Sancak et al., 2007). RAP-
TOR positively regulates mTOR activity and functions as 
a scaffold for recruiting mTORC1 substrates (Hara et al., 
2002; Kim et al., 2002; Schalm et al., 2003). PRAS40 
negatively regulates mTOR activity in a manner that 
depends upon its phosphorylation state (Haar et al., 
2007; Sancak et al., 2007). The molecular function of 
mLST8 is still ambiguous.
Upstream Regulation of mTORC1 Signaling
A major leap forward in understanding mTORC1 regula-
tion was the discovery that the TSC1 and TSC2 bipartite 
protein complex negatively controls its activity (Figure 1A) 
(reviewed in Crino et al., 2006). Mutations in either the 
tsc1 or tsc2 gene cause the hamartomatous syndrome 
tuberous sclerosis complex (TSC). The discovery of the 
connection between TSC and the mTORC1 pathway pro-
vided the first molecular link between mTOR and cancer.Cancer Cell 12, July 2007 ©2007 Elsevier Inc. 
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(A) The mTOR kinase is the catalytic component of two distinct multiprotein complexes called mTORC1 and mTORC2. (Left) In addition to mTOR, 
mTORC1 contains RAPTOR, mLST8, and PRAS40. mTORC1 drives cellular growth by controlling numerous processes that regulate protein synthe-
sis and degradation. Diverse positive and negative growth signals influence the activity of mTORC1, many of which converge upon the TSC1/2 com-
plex. (Right) mTORC2 also contains mLST8, but instead of RAPTOR and PRAS40, mTORC2 contains the RICTOR, mSIN1, and PROTOR proteins. 
Currently, the only characterized substrate of mTORC2 is the AKT kinase, which suggests mTORC2 functions downstream in the PI3K pathway to 
regulate cell growth, proliferation, and survival. mTORC2 also regulates PKCα phosphorylation, but it is not known if this is direct, or if mTORC2 can 
regulate other AGC-family kinases. Activation and inhibition induced by direct phosphorylation is indicated by a phosphate (P). 
(B) Model of mTORC1 coregulation by RHEB and PRAS40. (Left) When AKT is inactive, TSC1/2 inhibits RHEB while PRAS40 inhibits mTORC1. (Mid-
dle) Upon activation, AKT promotes mTORC1 activity by phosphorylating both TSC1/2 and PRAS40. This results in GTP-loading of RHEB, which 
directly activates mTORC1 and release of mTORC1 from PRAS40 repression. (Right) In tsc2 null cells, RHEB strongly activates mTORC1. This in 
turn inhibits AKT by way of the negative feedback loop (described in the text). Even though PRAS40 is dephosphorylated in this state, its ability to 
repress mTORC1 is overrun by the greatly elevated Rheb activity.TSC2 possesses GAP (GTPase activating protein) 
activity and inactivation of the TSC1/2 complex, either by 
mutation (as in TSC) or by cellular growth signals, leads 10 Cancer Cell 12, July 2007 ©2007 Elsevier Inc.to the activation of the ras-like GTPase RHEB (reviewed 
in Crino et al., 2006). A putative RHEB GEF (guanine 
nucleotide exchange factor) has been described in Dro-
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(Hsu et al., 2007). Although it is difficult to detect a direct 
biochemical interaction between endogenous RHEB-
GTP and mTORC1, in vitro experiments indicate that 
soluble GTP-loaded RHEB directly activates the kinase 
activity of mTORC1 (Figure 1B) (Sancak et al., 2007). 
In contrast, PRAS40 inhibits RHEB-GTP-dependent 
mTORC1 activation in a dose-dependent manner in an in 
vitro kinase assay, and it stably associates with mTORC1 
in cells (Haar et al., 2007; Sancak et al., 2007). Although 
RHEB-GTP and PRAS40 are adversaries in a cell free 
system, in intact normal cells, AKT forces them to coop-
erate. For instance, AKT (and possibly other kinases) 
phosphorylates PRAS40 on T246, diminishing its ability 
to inhibit mTORC1 (Haar et al., 2007; Huang and Por-
ter, 2005; Kovacina et al., 2003; Sancak et al., 2007). 
Therefore, AKT both promotes RHEB GTP-loading and 
relieves mTORC1 from PRAS40 repression, although it is 
not clear if this dual regulatory input functions in all cell 
types. Other subunits of mTORC1 are also phosphor-
ylated (including mTOR at S2448 [Sekulic et al., 2000], 
which is commonly used as a biomarker of mTOR activa-
tion), but the functional significance of these modifica-
tions is unclear.
Diverse signals regulate TSC1/2 suggesting that, 
like mTORC1, TSC1/2 is a signal integration center. 
Positive growth signals from the RAS-MAPK path-
way inhibit TSC2 (Ballif et al., 2005; Ma et al., 2005a; 
Roux et al., 2004). However, the phosphorylation and 
inhibition of TSC2 by AKT is the clearest link between 
mTORC1 and a pathway deregulated in cancer (Inoki et 
al., 2002; Manning et al., 2002). Aberrant AKT activa-
tion is a widespread oncogenic phenomenon that can 
result from pten deletion, pik3ca activating mutations, 
the bcr-abl translocation, and amplification of genes 
encoding HER-2, EGFR, or AKT itself (reviewed in 
Guertin and Sabatini, 2005). 
A growing body of evidence argues that the connection 
between AKT and TSC2-RHEB-mTORC1 is a critical step 
in PI3K-mediated tumorigenesis. For instance, rapamy-
cin slows the proliferation of transformed cells null for 
pten or expressing constitutively active AKT (reviewed 
in Guertin and Sabatini, 2005). Studies in mouse models 
support this idea showing that the neoplastic pheno-
types induced by pten deletion or transgenic activation 
of AKT are sensitive to rapamycin (Majumder et al., 2004; 
Neshat et al., 2001; Podsypanina et al., 2001). In mice, 
depletion of AKT activity can also thwart pten-deletion-
driven as well as RAS-driven and chemically induced 
tumorigenesis (Chen et al., 2006; Skeen et al., 2006). 
Based on in vitro studies in mouse embryo fibroblasts 
(MEFs), it is argued that the oncogenic activity of AKT in 
these models depends on mTORC1 (Skeen et al., 2006). 
The importance of AKT-dependent inhibition of PRAS40 
in tumorigenesis is not yet known but, interestingly, the 
PRAS40 gene is located in a region of chromosome 19 
(19q13.33) thought to contain an unidentified tumor sup-
pressor (Hartmann et al., 2002).In contrast to growth-factor-driven activation of 
mTORC1, hypoxia, AMPK activation resulting from 
depletion of cellular energy, WNT-GSK3 signaling, and 
glucocorticoids all inhibit mTORC1 by promoting TSC1/2 
activation (Inoki et al., 2006; Reiling and Sabatini, 2006; 
Wang et al., 2006). Amino acid deprivation may also 
activate TSC1/2, although other evidence argues that 
mTORC1 and S6K1 respond to amino acid availability 
independently of TSC1/2 (Findlay et al., 2007; Nobukuni 
et al., 2005; Sarbassov and Sabatini, 2005; Smith et al., 
2005) so how nutrients, particularly amino acids, regu-
late mTORC1 signaling remains a mystery.
Can cancer cells survive by acquiring adaptations 
that allow mTORC1 to continue signaling in nutrient and 
oxygen poor environments? Because deprivation for 
energy, oxygen, and nutrients is common in the micro-
environment of tumors, cancer cells insensitive to these 
stresses may have a selective growth advantage. On 
the other hand, transformed cells may restrict growth in 
a suboptimal environment, buying time to acquire other 
mutations and/or await angiogenesis. The lack of this 
response could be disadvantageous as it could lead 
to unrestricted growth signaling in poor nutrient condi-
tions, causing cells to deplete their energy stores and 
induce apoptosis. Consistent with this idea, tsc2-defi-
cient cells undergo apoptosis in glucose-free medium, 
a response suppressed by rapamycin (Inoki et al., 
2003). An additional mechanism tumor cells may use 
to cope with nutrient deprivation is to temporarily sal-
vage nutrients autonomously by activating autophagy 
(Liang et al., 2007).
Regulation of mTORC1 by Localization
The consensus from several independent studies is 
that mTOR is predominantly cytoplasmic but associ-
ated with cellular membranes including those of the 
mitochondria, endoplasmic reticulum, and Golgi (Desai 
et al., 2002; Drenan et al., 2004; Liu and Zheng, 2007; 
Sabatini et al., 1999; Tirado et al., 2003; Withers et al., 
1997). RHEB also associates with the endomembrane 
system (Buerger et al., 2006), and collectively, these 
studies suggest that mTORC1 signaling may emanate 
from intracellular membranes. Interestingly, a portion 
of mTOR shuttles between the nucleus and cytoplasm, 
and, by an unknown mechanism, this may regulate the 
ability of mTOR to phosphorylate S6K1 (Bachmann et 
al., 2006; Bernardi et al., 2006; Kim and Chen, 2000; Li 
et al., 2007).
Effectors of mTORC1
S6K1 and 4E-BP1—both regulators of mRNA trans-
lation—are the only extensively described mTORC1 
substrates (reviewed in Sarbassov et al., 2005a; Wul-
lschleger et al., 2006). The eIF3 complex facilitates 
mTORC1-dependent phosphorylation of S6K1 and 
4E-BP1 by functioning as a scaffold that mediates the 
enzyme-substrate interactions (Holz et al., 2005). When 
activated by mTORC1, S6K1 promotes protein synthe-
sis by phosphorylating PDCD4 and targeting it for deg-
radation (Dorrello et al., 2006). PDCD4 hinders protein Cancer Cell 12, July 2007 ©2007 Elsevier Inc. 11
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 Upstream and Downstream of AKT
(A) Full activation of AKT requires phosphoryla-
tion on two sites, T308 by PDK1 and S473 by 
mTORC2. Activated AKT phosphorylates many 
substrates including TSC2 and the FOXOs. Akt 
phosphorylates mTORC1 directly, but this connec-
tion is just beginning to be understood. 
(B) Eliminating mTORC2 ablates AKT S473 phos-
phorylation in mouse embryo fibroblasts. This 
does not affect the phosphorylation of TSC2. In 
contrast, one AKT phosphorylation site in the 
FOXO1 and FOXO3 transcription factors is re-
duced, while phosphorylation at another AKT site 
is unaffected. One possible model to explain this 
finding is that S473-unphosphorylated AKT retains 
enough catalytic activity to phosphorylate some of 
its targets but not others. 
(C) Alternatively, a substitute kinase, which is 
likely to be regulated by PDK1, can compensate 
for S473-deficient AKT. In the case of FOXO, it is 
known that SGK can phosphorylate some of the 
same sites as AKT.translation by binding and preventing the eIF4A helicase 
from unwinding secondary structure in the 5′ untranslated 
region of mRNA. The ribosomal protein S6 is perhaps the 
best-known S6K1 substrate. Despite being an indirect 
measure of mTORC1 activity and lacking a clear function, 
S6 phosphorylation is widely used in research and in the 
clinic as a biomarker of mTORC1 activity. In addition to 
S6K1, mTORC1 phosphorylates 4E-BP1 and releases it 
from inhibiting the elongation initiation factor 4E (eiF4E).
mTORC1 also drives protein synthesis by regulating 
ribosome biogenesis. In yeast, TORC1 activity pro-
motes the synthesis of ribosomal proteins, and in higher 
organisms this may additionally or alternatively involve 
regulating ribosome assembly (Guertin et al., 2006a; 
Wullschleger et al., 2006). Other mTORC1 substrates 
include CLIP-170, LIPIN, and STAT3, but their roles in 
mTORC1 signaling are less characterized (Choi et al., 
2002; Huffman et al., 2002; Yokogami et al., 2000). The 
dearth of well-known mTORC1 substrates might reflect 
the fact that the mTORC1 target sites are structurally 
diverse and difficult to identify bioinformatically (for 
example, the phosphorylation sites in S6K1 and 4E-BP1 
are dissimilar).
Negative Feedback Regulation of PI3K-AKT 
Signaling
It might seem surprising that patients suffering from TSC 
do not develop more aggressive tumors, like those linked 
to pten mutations. The reason may be the existence of a 
potent negative feedback loop. In many cell types, acti-
vation of mTORC1 signaling strongly represses PI3K-
AKT signaling upstream in the PI3K pathway (reviewed 
in Manning, 2004). For example, loss of TSC1/2 function 
results in decreased AKT phosphorylation (Jaeschke et 
al., 2002; Kwiatkowski et al., 2002). One mechanism by 
which this occurs appears to be through S6K1-depend-
ent downregulation of IRS-1 (Figure 1A). When mTORC1 
is active, S6K1 directly phosphorylates and inhibits IRS-
1 (reviewed in Zick, 2005). Mice lacking s6k1 are viable, 
but when challenged with a high-fat diet, despite the 12 Cancer Cell 12, July 2007 ©2007 Elsevier Inc.fact that insulin receptors become desensitized, they are 
resistant to obesity because loss of the feedback loop 
enhances their insulin sensitivity (Um et al., 2004). These 
observations led to the hypothesis that tumors in TSC 
patients are less aggressive because the feedback loop 
squelches PI3K-AKT signaling. Genetic evidence in mice 
supports this hypothesis as inactivation of pten in tsc2-
deficient lesions elevates AKT signaling sufficiently to 
overcome the feedback loop and results in more severe 
tumors (Ma et al., 2005b; Manning et al., 2005). Other 
receptor tyrosine kinase pathways that do not depend 
on IRS-1 are also likely subject to mTORC1-dependent 
negative regulation. For instance, tsc1/2 deletion sup-
presses PDGFR expression in a rapamycin-sensitive 
manner (Zhang et al., 2007).
Regulation of mTORC1 by PRAS40 may have an 
important role in setting the level of feedback inhibition. 
PRAS40 functions as an mTORC1 inhibitor, but its inhibi-
tory duty is relieved upon being phosphorylated by AKT. 
Therefore, a decrease in AKT activity—as would occur 
during negative feedback inhibition—might enhance 
mTORC1 inhibition by PRAS40 and in turn, decrease the 
level of feedback inhibition. One study using siRNA to 
deplete cells of TSC2 or overexpressing recombinant 
RHEB finds that in each case, simultaneously overex-
pressing recombinant PRAS40 suppresses mTORC1 
activation (Haar et al., 2007). However, in cells deleted 
for the tsc2 gene, PRAS40-dependent inhibition of 
mTORC1 is completely overrun by the greatly elevated 
level of RHEB activation (Figure 2B) (Sancak et al., 
2007). Nevertheless, PRAS40 may influence the magni-
tude of feedback inhibition in a cell-type-specific man-
ner, although this remains to be seen.
mTORC2 Signaling in Cancer
Regulation of AKT by mTORC2
Study of mTORC2 is in its infancy, but the finding that 
mTORC2 directly phosphorylates AKT adds a new twist 
in thinking about the role of mTOR in cancer (Sarbassov 
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mLST8 protein, but instead of RAPTOR, mTORC2 con-
tains the RICTOR (rapamycin-insensitive companion of 
mTOR) and mSIN1 proteins (Frias et al., 2006; Jacinto 
et al., 2004, 2006; Sarbassov et al., 2004; Yang et al., 
2006). mTORC2 additionally contains PROTOR (protein 
observed with RICTOR), a protein found only in higher 
eukaryotes that lacks any obvious functional domains 
(Pearce et al., 2007).
Phosphorylation of S473 in a C-terminal hydrophobic 
motif is necessary for the full activation of AKT (Alessi 
et al., 1996). Several kinases have been proposed to 
fulfill the role of the AKT S473 kinase—the so-called 
“PDK2 kinase.” mTOR was added to the list as a result 
of loss-of-function RNAi experiments coupled with in 
vitro biochemistry in Drosophila and human cancer cells 
(Sarbassov et al., 2005b). This study and ensuing work 
in human adipocytes and Dictostylium show that deple-
tion of RICTOR or mTOR, but not RAPTOR, dramatically 
reduces Akt S473 phosphorylation (Figure 1A) (Hresko 
and Mueckler, 2005; Lee et al., 2005; Sarbassov et al., 
2005b). The discovery that SIN1 functions in TORC2-
mediated regulation of AKT emerged from a study in Dic-
tostylium, which found that RIP3 and PIA, the orthologs 
of mSIN1 and RICTOR, respectively, physically interact 
in a complex, and when mutated, induce similar phe-
notypes including impaired AKT activation (Lee et al., 
2005). Subsequent biochemical studies in mammalian 
and Drosophila cultured cells confirm these observa-
tions (Frias et al., 2006; Jacinto et al., 2006; Yang et al., 
2006). It has not yet been determined if PROTOR func-
tions in the regulation of AKT.
The recently described PHLPP phosphatases 
(PHLPP1 and PHLPP2) counteract mTORC2 by dephos-
phorylating AKT at S473 (Brognard et al., 2007; Gao et 
al., 2005). Understanding the interplay between these 
two forces is of obvious importance. In mammals, there 
are three AKT isoforms, each encoded by a unique 
gene (Hanada et al., 2004). Interestingly, PHLPP1 and 
PHLPP2 reportedly have different specificities for the 
three AKT isoforms (Brognard et al., 2007; Gao et al., 
2005). An understanding of how the isoforms of AKT are 
differentially regulated may have important implications 
in cancer; however, because most studies of AKT do not 
differentiate between the different isoforms, it is difficult 
to speculate on what those implications might be.
Most of the known core mTOR interacting proteins, 
except for PRAS40 and PROTOR, have been knocked 
out in mice. Deleting the mtor gene results in embryonic 
lethality around the time of implantation, thus preclud-
ing the ability to measure AKT phosphorylation in mtor 
null tissues (Gangloff et al., 2004; Murakami et al., 2004). 
The early lethality of mtor null mice appears to result 
from a loss of mTORC1 function because raptor null 
mice are phenotypically similar (Guertin et al., 2006b). 
In contrast, mTORC2-deficient mice survive until midg-
estation (Guertin et al., 2006b; Jacinto et al., 2006; Shi-
ota et al., 2006; Yang et al., 2006). Importantly, deletion of the genes encoding mTOR interacting proteins that 
define mTORC2 (rictor, mlst8, and msin1) ablates AKT 
S473 phosphorylation (Guertin et al., 2006b; Jacinto et 
al., 2006; Shiota et al., 2006; Yang et al., 2006). These 
findings provide strong genetic evidence in mammals to 
substantiate the claim that mTORC2 directly regulates 
AKT.
An unexpected finding from the genetic knockout stud-
ies is that mLST8, a stable component of both mTORCs, 
is functionally required only for mTORC2 signaling in 
development (Guertin et al., 2006b). lst8 null budding 
yeast and Dictyostelium cells are also phenotypically 
more similar to cells deleted for TORC2-specific compo-
nents (Lee et al., 2005; Loewith et al., 2002). However, at 
least one TORC1-specific function is still impaired in lst8 
null budding yeast cells (Loewith et al., 2002). Moreover, 
depletion of mLST8 in cultured human cancer cells also 
impairs mTORC1 signaling (Jacinto et al., 2004; Kim et 
al., 2003) suggesting that mLST8 may have a role, albeit 
mysterious, in both complexes.
AKT belongs to a family of structurally related kinases 
called the AGC kinases, which includes the S6Ks, SGKs, 
RSKs, and PKCs (Hanada et al., 2004). All family mem-
bers contain the hydrophobic motif phosphorylation site 
(S473 in AKT; T389 in S6K1), as well as a phosphoryla-
tion site for the PDK1 kinase in the kinase domain (T308 
in AKT; T229 in S6K1). S6K1 contains an additional C-
terminal inhibitory domain that is absent in the other fam-
ily members, and this domain may preferentially recruit 
S6K1 to the mTORC1 complex (Ali and Sabatini, 2005). 
Whether other AGC kinases are targeted by mTOR is 
an open question. However, knockdown and knockout 
studies indicate that mTORC2 regulates PKCα phospho-
rylation and stability, although it is not known if this is 
direct (Guertin et al., 2006a; Sarbassov et al., 2004).
Growth factors stimulate mTORC2 activity and some 
mTORC2 subunits are phosphorylated, but the respon-
sible kinases remain unknown (Frias et al., 2006; Sar-
bassov et al., 2004; Sarbassov et al., 2005b; Yang et al., 
2006). In Dictyostelium, the mSIN1 homolog (RIP3) inter-
acts with RAS-GTP in a two-hybrid assay and recom-
binant RIP3 proteins harboring mutations in the Ras 
binding domain do not fully rescue rip3− cells (Lee et al., 
1999, 2005; Schroder et al., 2007). This raises the pos-
sibility that RAS regulates mTORC2. Additionally, three 
mSIN1 isoforms independently interact with mTOR and 
RICTOR, defining three distinct mTORC2s (Frias et al., 
2006; Schroder et al., 2004). All three mTORC2s phos-
phorylate AKT S473 in vitro, but insulin activates only 
two of them (Frias et al., 2006). Thus, some mTORC2 
complexes may phosphorylate AKT independently of 
growth factor stimulation. Curiously, the mSIN1 isoform 
that defines the insulin-independent mTORC2 is trun-
cated at the C terminus and lacks part of the ras-binding 
domain as well as a putative, but divergent, PH domain 
(Frias et al., 2006; Schroder et al., 2007). An interesting 
possibility is that these mSIN1 C-terminal domains link 
mTORC2 to growth factor stimuli.Cancer Cell 12, July 2007 ©2007 Elsevier Inc. 13
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Full AKT activity in vitro requires phosphorylation at both 
T308 and S473 (Alessi et al., 1996). However, unlike the 
case for S6K, SGK, and RSK, phosphorylation of AKT 
at T308 by PDK1 is not contingent upon prior phos-
phorylation at S473 (Biondi et al., 2001; Collins et al., 
2003). Phosphorylation of S473 occurs in pdk1 null cells 
in which T308 phosphorylation is abolished (Alessi et 
al., 1996; McManus et al., 2004). Moreover, ablation of 
S473 phosphorylation that occurs upon deleting rictor, 
mlst8, or msin1 does not eliminate T308 phosphoryla-
tion (Guertin et al., 2006b; Jacinto et al., 2006; Shiota et 
al., 2006). These results suggest that these two phos-
phorylation events may occur independently and sup-
port a model in which AKT and PDK1 interact as a result 
of colocalization to the plasma membrane (through their 
PH domains) (Collins et al., 2003). Once colocalized, 
PDK1 activates AKT, which is synergistically enhanced 
by mTORC2. It is not known how the interaction between 
mTORC2 and AKT is facilitated, but one possibility is 
that the PH-like domain of mSIN1 localizes mTORC2 
with AKT at membranes (Schroder et al., 2007).
In contrast to the results obtained from studying 
knockout MEFs, reducing mTORC2 activity in cultured 
cancer cells by depleting RICTOR or mTOR by RNAi 
simultaneously decreases phosphorylation at both the 
PDK1 site (T308) and the mTORC2 site (S473) (Hresko 
and Mueckler, 2005; Sarbassov et al., 2005b). This dis-
crepancy may reflect a fundamental difference between 
depletion of mTORC2 activity acutely using RNAi versus 
chronically by gene knockout. However, an interesting 
possibility is that immortalization might rewire the cel-
lular circuitry such that T308 and S473 phosphorylation 
become linked. This might suggest that an mTORC2-
inhibitor could be more toxic to cancer cells than to nor-
mal cells.
mTOR May Function on Both Sides of AKT 
In cultured mammalian cells, the expression of a recom-
binant mutant of TSC2 incapable of being phosphor-
ylated by AKT dramatically reduces mTORC1-depend-
ent phosphorylation of a coexpressed recombinant 
version of S6K1 (Manning et al., 2002). Combined with 
the finding that mTORC2 phosphorylates S473 of AKT, 
this suggests a model in which mTOR may function both 
upstream and downstream of AKT (Figure 2A).
However, challenging the universality of this model 
is the surprising finding from mouse genetic studies 
that deleting rictor, mlst8, or msin1 does not affect the 
phosphorylation of TSC2 on two well-characterized AKT 
target sites (S939 & T1462), despite the fact that AKT 
S473 phosphorylation is ablated in MEFs (Guertin et al., 
2006b; Inoki et al., 2002; Jacinto et al., 2006; Manning et 
al., 2002). Similarly, phosphorylation of AKT target sites 
in GSK3α and GSK3β (S9 and S21, respectively) are also 
unaffected. In contrast, all three deletions reduce phos-
phorylation on one predicted AKT phosphorylation site 
of the Forkhead O (FOXO) transcription factors FOXO1 
and FOXO3 (T24 and T32, respectively), while phospho-14 Cancer Cell 12, July 2007 ©2007 Elsevier Inc.rylation at another (S256) is unimpaired. These findings 
raise some interesting questions:
How does S473 phosphorylation by mTORC2 regu-
late AKT activity in vivo? Perhaps S473-unphosphor-
ylated AKT is partially active in vivo. For example, Akt 
lacking S473 phosphorylation may possess enough 
intrinsic activity to phosphorylate TSC2, but FOXO1/3 
phosphorylation on T24/32 may require a higher thresh-
old of Akt activity (Figure 2B). In addition or alterna-
tively, S473-phosphodeficient Akt may be incapable of 
making a protein-protein interaction or missing a local-
ization signal that is necessary for phosphorylating 
FOXO/3. In Drosophila, AKT is required for viability, but 
surprisingly, dTORC2 is not (Hietakangas and Cohen, 
2007; Staveley et al., 1998). Thus, dAKT lacking the HM 
phosphorylation (S505 in Drosophila) retains all essen-
tial biological activities, consistent with a model that 
not all in vivo functions of AKT require HM phospho-
rylation. Interestingly, deletion of drictor rescues the 
overgrowth phenotypes associated with overexpress-
ing dpi3k or deleting dpten, suggesting that dTORC2 
becomes limiting only when dPI3K signaling is high 
(Hietakangas and Cohen, 2007).
Another possibility is that a compensatory kinase 
may fill in for S473 phosphodeficient AKT in some cases 
(Figure 2C). For example, phosphorylation sites in GSK3 
and mTOR first identified as AKT target sites can also be 
phosphorylated by S6K1 (Chiang and Abraham, 2005; 
Holz and Blenis, 2005; Zhang et al., 2006). Moreover, 
both SGK and AKT can phosphorylate some of the 
same sites in FOXO1/3 (reviewed in Greer and Brunet, 
2005). Thus, one property of AGC kinases appears to 
be their ability to share substrates in certain circum-
stances. Importantly, phosphorylation of TSC2, GSK3, 
and FOXO1/3 at the predicted AKT sites requires PDK1 
(McManus et al., 2004). Thus, if an alternative kinase 
phosphorylates these sites it is likely to be an AGC fam-
ily member. How other AKT substrates (e.g., PRAS40, 
BAD, IκB, p21Cip1, and p21Kip1) respond to losing mTORC2 
function still needs to be addressed.
It is possible that TSC2 is not always a critical AKT 
target. In Drosophila, replacement of wild-type TSC2 
with a mutant version in which the AKT phosphoryla-
tion sites were changed to nonphosphorylatable resi-
dues did not impair development (Dong and Pan, 2004). 
Moreover, the activation of AKT impairs neuronal growth 
and this phenocopies losing TSC1/2 function, but this 
effect does not require AKT-dependent phosphoryla-
tion of TSC2 at S939 or T1462 (Tavazoie et al., 2005). 
Since mTORC1 also binds the Akt substrate PRAS40, 
this raises the possibility that AKT could bypass TSC1/2 
and signal directly to mTORC1 (Haar et al., 2007; Sancak 
et al., 2007). Thus, the role of AKT-dependent phosphor-
ylation of TSC2 in mTORC1 regulation is still uncertain.
Because ablation of mTORC2 activity reduces 
FOXO1/3 T24/32 phosphorylation in MEFs, this might 
suggest that FOXOs are important targets of AKT in 
development. Interestingly, activating mutations in PI3K 
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nism that selectively requires AKT signaling to FOXO1/3 
(Samuels et al., 2005). Taken together, these findings 
might further suggest that FOXO1/3 is a critical AKT tar-
get in some cancers. FOXO transcription factors, which 
regulate the cell cycle, apoptosis, and metabolism, and 
appear to function in angiogenesis among other proc-
esses, are inhibited by AKT (Furuyama et al., 2004; 
Greer and Brunet, 2005; Hosaka et al., 2004; Potente et 
al., 2005). Mice deleted for the foxO1, foxO3, and foxO4 
genes develop thymic lymphomas and hemangiomas, 
unequivocally demonstrating that foxOs are tumor sup-
pressors (Paik et al., 2007; Tothova et al., 2007). How-
ever, the tumor spectrum in foxO1/3/4 triple knockout 
mice is more restricted compared with that seen in pten-
deficient mice (Di Cristofano et al., 1998; Podsypanina et 
al., 1999; Suzuki et al., 1998), possibly suggesting that 
FOXOs are critical AKT targets in some cancers and not 
others, or that other PIP3-activated pathways contribute 
to the tumor burden seen in pten-deficient mice.
mTOR Inhibitors in Cancer Therapy
Clinical results with three prototype mTOR inhibitors, all 
rapamycin analogs (CCI-779 [Wyeth], RAD001 [Novartis], 
AP23573 [Ariad Pharmaceuticals]), have been described 
(reviewed in Easton and Houghton, 2006; Faivre et al., 
2006; Granville et al., 2006; for simplicity, we will refer to 
all analogs as rapamycin from here on). Unfortunately, 
clinical updates indicate that rapamycin shows promise 
against only a few cancers, particularly mantle cell lym-
phoma, endometrial cancer, and renal cell carcinoma. 
Overall, the therapeutic response to rapamycin is highly 
variable, suggesting that biomarkers capable of pre-
dicting which cells will respond to rapamycin-therapy 
are needed. While current results are frustrating, they 
likely reflect the fact that we do not fully understand 
the mechanism of action of rapamycin or mTOR cir-
cuitry. Unexpectedly, prolonged exposure to rapamy-
cin decreases AKT S473 phosphorylation in a subset 
of cancer cells (Sarbassov et al., 2006). This appears 
to result from the capacity of rapamycin to block the 
assembly of mTORC2 (Sarbassov et al., 2006). A major 
and problematic question though is why mTORC2 is 
susceptible to prolonged rapamycin exposure in some 
cells, partially sensitive in some cells, and resistant in 
others (Sarbassov et al., 2006). Complicating this ques-
tion is the fact that no genetic traits predictive of this 
phenomenon have been identified. Regardless, this 
finding challenges conventional wisdom that rapamycin 
is an mTORC1-specific inhibitor, and invites speculation 
that some of the clinical responses to rapamycin may 
reflect this dual action of the drug.
Hamartoma Syndromes
The clearest molecular rationale for rapamycin therapy 
exists for hamartoma syndromes such as tuberous scle-
rosis complex. There are several hamartoma syndromes 
that share pathological features with TSC, including 
Cowden Disease, Peutz-Jeghers Syndrome, neurofi-bromatosis, and Birt-Hogg-Dube Syndrome. Like tsc1 
and tsc2, the tumor suppressor genes linked to these 
diseases (pten, lkb1, nf1, and flcn respectively) encode 
proteins that restrict mTORC1 signaling (Baba et al., 
2006; Corradetti et al., 2004; Eng, 2003; Johannessen et 
al., 2005; Shaw et al., 2004). Clinical trials with rapamy-
cin are underway for treating some of these conditions 
and early reports from TSC trials indicate promising suc-
cesses (Franz et al., 2006).
Angiogenesis
A particularly interesting property of rapamycin is its 
ability to suppress angiogenesis (Guba et al., 2002). 
In cells exposed to hypoxia, levels of the HIF1α tran-
scription factor increase and this facilitates expression 
of VEGF, a HIF1α target gene. mTORC1 regulates the 
translation and activity of HIF1α (Bernardi et al., 2006; 
Hudson et al., 2002), suggesting that the antiang-
iogenic properties of rapamycin could result from its 
ability to disrupt vegf expression. A remarkable suc-
cessful example of treating tumors using rapamycin 
is in Kaposi’s sarcoma (KS), a tumor characterized 
by high vascularization and increased vegf signaling 
(Campistol et al., 2004; Stallone et al., 2005). Rapamy-
cin may also be particularly effective in treating certain 
kidney cancers. Many cases of sporadic kidney cancer 
(50%–60%) exhibit loss of the VHL (Von Hippel-Lindau) 
tumor suppressor, which encodes a negative regulator 
of HIF1α (Kim and Kaelin, 2004). In a xenograft model 
using human kidney cancer cells, loss of VHL expres-
sion correlates with elevated HIF1α levels, an increased 
vascular network, and importantly, with rapamycin sen-
sitivity (Thomas et al., 2006). In this model, rapamy-
cin appears to function by inhibiting the translation of 
HIF1α, which correlates with a drop in VEGF expres-
sion and reduced angiogenesis. VHL expression might 
therefore be predictive of which kidney cancer patients 
will respond favorably to rapamycin therapy.
Interestingly, endothelial cells are one of the clearest 
examples of a cell type in which AKT phosphorylation is 
susceptible to mTORC2 inhibition by prolonged rapamy-
cin treatment (Sarbassov et al., 2006). AKT is important 
for VEGF-mediated angiogenesis and KS requires AKT 
hyperactivation in endothelial cells (Ackah et al., 2005; 
Sodhi et al., 2004). Rapamycin treatment blocks patho-
logical angiogenesis and decreases tumor growth in a 
xenograft model by decreasing AKT S473 phosphor-
ylation in the endothelial cells surrounding the tumor 
(Phung et al., 2006). The inhibition of mTORC2-AKT 
signaling by rapamycin in endothelial cells suggests an 
alternative explanation for the antiangiogenic properties 
of the drug and emphasizes the potential importance of 
the mTORC2-AKT-FOXO circuit in these cells. A nota-
ble characteristic of mice deficient for mTORC2 or AKT 
activity is an underdeveloped fetal vascular system 
(Guertin et al., 2006b; Shiota et al., 2006; Yang et al., 
2003, 2005). Given the demonstrated role of mTORC2 
in FOXO1/3 phosphorylation and the fact that foxO1/3/4 
triple knockout mice are predisposed to developing Cancer Cell 12, July 2007 ©2007 Elsevier Inc. 15
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cin-sensitive mTORC2-AKT-FOXO circuit may be essen-
tial for endothelial cell function. However, the causative 
agent in KS (a G protein coupled receptor) can stimulate 
TSC2 phosphorylation and mTORC1 activation (Sodhi et 
al., 2006). Thus, a role for the mTORC1 pathway in patho-
logical angiogenesis, at least in KS, cannot be ruled out. 
In fact, depleting endothelial cells of RAPTOR (mTORC1) 
or RICTOR (mTORC2) by RNAi reveals that both mTORCs 
function in hypoxia-induced proliferation, but the role of 
mTORC1 is early and transient, while mTORC2-AKT sig-
naling is sustained and critical (Li et al., 2007). Therefore, 
the dual inhibitory action of rapamycin on both mTORCs 
may be the key to its antiangiogenic properties (Figure 
3). A direct mTOR kinase domain inhibitor may therefore 
be an effective angiogenesis inhibitor.
Hematopoietic Cancers 
Patients suffering from mantle-cell lymphoma (MCL) 
exhibit one of the best clinical responses to rapamycin 
(Witzig et al., 2005; Witzig and Kaufmann, 2006). MCL 
is a non-Hodgkin’s lymphoma with the poorest progno-
sis among the non-Hodgkin’s lymphomas (Williams and 
Densmore, 2005). The disease is characterized by high 
CYCLIN D1 expression and currently there is no stand-
ard treatment. Treatment of MCL cells with rapamycin in 
vitro induces cell cycle arrest, but unexpectedly, without 
affecting CYCLIN D1 levels (Hipp et al., 2005). AKT sig-
Figure 3. Rapamycin May Block Pathological Angiogenesis 
by Inhibiting Both mTORC1 and mTORC2
Studies in the laboratory and in the clinic indicate that rapamycin 
blocks pathological angiogenesis. The dual inhibitory action of ra-
pamycin on both mTORC1 and mTORC2 may be the key to its an-
tiangiogenic properties. Rapamycin, which is pharmacologically ac-
tive only when bound to the immunophilin (FKBP12), is a universal 
mTORC1 inhibitor. In endothelial cells, rapamycin additionally blocks 
mTORC2 assembly and inhibits full AKT activation. In cultured en-
dothelial cells, mTORC1 is required early and transiently for hypoxia-
induced proliferation, but the requirement for mTORC2 is sustained 
and more critical.16 Cancer Cell 12, July 2007 ©2007 Elsevier Inc.naling is also enhanced in many mantle-cell lymphoma 
lines, although rapamycin’s affect on AKT in these 
cells has not been investigated (Rudelius et al., 2006). 
Rapamycin is also a potential treatment for acute myel-
ogenous leukemia (AML). The PI3K-AKT-mTOR pathway 
is hyperactive in patient-derived AML cells, and in vitro, 
AML cells respond favorably to the drug (Recher et al., 
2005). Like in endothelial cells, rapamycin inhibits both 
the mTORC1-S6K1 and mTORC2-AKT pathways in AML 
cells (Zeng et al., 2007), suggesting that a positive clini-
cal response in AML may correspond with the drug’s 
ability to additionally inhibit mTORC2.
Deletion of pten in adult mouse hematopoietic cells 
induces hematopoietic stem cell (HSC) proliferation 
and the generation of leukemia-initiating cells, leading 
to depletion of normal HSCs and causing a myoprolif-
erative disease that eventually progresses to leukemia 
(Yilmaz et al., 2006). Rapamycin treatment reverses this 
effect by both diminishing the number of leukemia-ini-
tiating cells and restoring normal HSC function. Dele-
tion of foxO1/3/4 in adult mouse hematopoietic cells 
results in a HSC defect phenotypically similar to the 
pten-deficient HSC model (Tothova et al., 2007). Thus, 
losing FOXO function rather than activating the mTORC1 
pathway may be the reason for the HSC defects in these 
mice. Perhaps HSCs, like endothelial cells, have a critical 
rapamycin-sensitive mTORC2-AKT-FOXO circuit, which 
could explain the effects of rapamycin in the pten-defi-
cient HSC model. If the effect of rapamycin in the pten-
deficient HSC model results from inhibiting mTORC2, 
then rapamycin should not revert the HSC phenotype 
in the foxO1/3/4-deletion model because it would func-
tion upstream of FOXO. It will be interesting to see if 
mTORC1, and in particular mTORC2, have roles in main-
taining other adult or embryonic stem cell populations.
The Future of Targeting mTOR in Cancer 
Rapamycin derivatives will likely be the first mTOR 
inhibitors to reach the market as cancer therapeutics. 
Rapamycin is a universal inhibitor of mTORC1-depend-
ent S6K1 phosphorylation, but the existence of the 
strong negative feedback loop from S6K1 to AKT signal-
ing presents a potential therapeutic problem as losing 
feedback inhibition of AKT could promote cell survival 
and chemoresistance. Clearly an undesirable response! 
Some studies suggest that sometimes this may be the 
case. For instance, rapamycin protects Jurkat cells from 
FAS/APO-1 death receptor activation or mitochondrial 
stress induced apoptosis (Fumarola et al., 2005). Fur-
thermore, rapamycin restores AKT signaling and NK-κB 
activation in tsc2-deficient cells, protecting them from 
DNA-damaged induced cell death (Ghosh et al., 2006). 
Although the release of AKT from feedback inhibition 
by an mTORC1 inhibitor is a legitimate concern, there is 
currently no clinical data corroborating this suspicion.
The finding that prolonged rapamycin treatment 
inhibits mTORC2 assembly and AKT phosphorylation 
in some cell types suggests the intriguing and per-
haps provocative idea that some clinical responses 
Cancer Cell
Reviewto rapamycin result from inhibiting both mTORCs. A 
recent study finds that rapamycin curtails progres-
sion of tobacco carcinogen-induced tumors in mice, 
and this too correlates with reduced AKT S473 phos-
phorylation (Granville et al., 2007). The implications 
of this and aforementioned observations are impor-
tant since current rapamycin trials are based on the 
premise that rapamycin is an mTORC1-specific inhibi-
tor. The absence of biomarkers to predict in which cells 
mTORC2 is sensitive to prolonged rapamycin expo-
sure, and the fact that mTORC2 inhibition by rapamy-
cin is inseparable from mTORC1 inhibition, currently 
complicates our understanding of this phenomenon. 
While mysterious, this idiosyncrasy in the mechanism 
of function of rapamycin may provide a valuable clue to 
finding cancers that will respond to the drug.
Dual inhibition of the PI3K pathway or other signaling 
pathways and mTOR could be an effective strategy (Fan 
and Weiss, 2006; Wan et al., 2007). This strategy avoids 
the potential consequences of disengaging the feed-
back loop. Drugs currently being considered for combi-
nation therapy include gefitinib (Iressa, an EGFR inhibi-
tor), imatinib mesylate (Gleevec, a BCR-ABL inhibitor), 
tamoxifen (estrogen receptor modulator), cisplatin (DNA 
damaging agent), and paclitaxel (microtubule stabilizer) 
(reviewed in Faivre et al., 2006; Granville et al., 2006). 
Perhaps a more versatile drug would be an ATP-com-
petitive mTOR inhibitor. A molecule of this nature would 
have the distinct advantage of inhibiting the full gamut of 
mTOR catalytic activities, although it is unclear if such a 
drug could be tolerated. Another strategy is to obstruct 
the binding of mTOR-interacting proteins, but the lack 
of mTORC structural information is a major challenge to 
developing this class of inhibitors.
Because AKT activation is widespread in cancer, 
there is also a rationale for developing an mTORC2-
specific inhibitor. Such a molecule might be well tol-
erated since decreasing mTORC2 activity seems to 
inhibit transformed cells more severely than MEFs 
(Guertin et al., 2006b; Hresko and Mueckler, 2005; 
Jacinto et al., 2006; Sarbassov et al., 2005b). The 
finding that TORC2 is not essential in Drosophila, but 
becomes essential for phenotypes dependent on ele-
vated dPI3K activity, further suggests the possibility 
that mTORC2 inhibitors might have therapeutic poten-
tial, particularly in cancers “addicted” to elevated 
PI3K signaling (Hietakangas and Cohen, 2007). While 
it is exciting to speculate on strategies to target mTOR 
in cancer, it is clear from several recent studies that 
many mysteries must be solved so that these strate-
gies can be rationally designed.
The Evolution of mTOR Signaling
As judged by the role of TORC1 in yeast, mTORC1 is 
an ancient controller of cell growth that is regulated 
by nutrients. Interestingly, TSC1/2-dependent regula-
tion of TOR is intact in fission yeast (S. pombe) but not 
in budding yeast (S. cerevisiae), suggesting S. pombe may hold important clues to how TOR signaling evolved 
(Urano et al., 2005; Uritani et al., 2006). Although the 
ancient function of mTORC2 is unclear, it too may have 
evolved from a nutrient-sensing pathway that became 
rewired through evolution to indirectly sense nutrients 
by way of growth factors. When elevated glucose levels 
are detected in the bloodstream, the pancreas secretes 
insulin, which activates the PI3K-mTORC2-AKT path-
way in peripheral tissues. AKT, in turn, suppresses 
apoptosis, promotes an influx of glucose and amino 
acids into the cell, stimulates ATP production, and per-
haps relieves mTORC1 from TSC1/2- and/or PRAS40-
dependent inhibition. Incoming nutrients subsequently 
activate the mTORC1-S6K1 growth engine. By way 
of negative feedback mechanisms, mTORC1 inhibits 
the insulin receptor-PI3K pathway, balancing nutrient 
intake with expenditure. The mTORC2-AKT circuit could 
therefore be an important link between cell autono-
mous and systemic nutrient sensing by mTOR (Figure 
4). Of course, not all cell types are equally responsive 
to growth factor stimulation or nutrient uptake and 
there could be different tissue-specific requirements 
for mTORC2 signaling. It would be interesting to com-
pare the role of the mTORCs in cancer cells originating 
from tissues with different sensitivities to insulin and 
nutrients, or in cancer cells with mutations in different 
growth factor signaling pathways.
Figure 4. Linking Cell Autonomous and Systemic Nutrient 
Sensing by mTOR
mTORC1 is an ancient regulator of cell growth that is activated by in-
tracellular nutrients. The ancient function of mTORC2 is unclear, but it 
may have evolved to indirectly sense nutrients by way of insulin sign-
aling. Circulating glucose triggers the release of insulin into the blood-
stream. In peripheral tissues harboring growth factor responsive cells, 
insulin activates the PI3K-mTORC2-AKT pathway. In individual cells, 
activation of AKT promotes survival, nutrient influx, and energy (ATP) 
generation. Signals from intracellular nutrients, energy, and from AKT 
itself subsequently activate mTORC1, which drives protein synthesis 
and promotes cell growth. Negative feedback mechanisms modulate 
PI3K-AKT activity, which may serve to balance nutrient intake with 
expenditure. Since all cells are not equally response to insulin or nu-
trients, cells originating from diverse tissues may have differential re-
quirements for each mTOR complex.Cancer Cell 12, July 2007 ©2007 Elsevier Inc. 17
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Despite knowing about mTOR for nearly 15 years, we 
are just beginning to appreciate the complexity of the 
mTOR network. Since AKT activates mTORC1 by phos-
phorylating and inhibiting TSC1/2, and mTORC2 phos-
phorylates and activates AKT, mTOR may function 
both upstream and downstream of AKT. Defining these 
complex and perhaps cell-type-specific connections 
between mTORC1 and mTORC2 is an important chal-
lenge for the future. It is also becoming clear that the 
mTORC1 inhibitor rapamycin has an unforeseen capabil-
ity to inhibit mTORC2, but only in a subset of cells. The 
dual sensitivity of the mTORCs to rapamycin is particu-
larly evident in endothelial cells, which is emphasized by 
the antiangiogenic property of rapamycin. Collectively, 
these findings are changing the view of the pathological 
role that mTOR plays in cancer and opening the door to 
new therapeutic strategies.
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